{
    "meta": {
        "portal_name": "pharmacodynamics",
        "language": "en",
        "updated": "20150502"
    },
    "schema": {
        "html:portal": "http://en.recuweb.com/pharmacodynamics/",
        "graph:videos": "http://en.recuweb.com/graph/v1.0/pharmacodynamics/pharmacodynamics/videos.json",
        "graph:news": "http://en.recuweb.com/graph/v1.0/pharmacodynamics/pharmacodynamics/news.json",
        "graph:blogs": "http://en.recuweb.com/graph/v1.0/pharmacodynamics/pharmacodynamics/blogs.json"
    },
    "items": {
        "streetwisereport.com/2015/04/active-runners-regulus-therapeutics-inc-nasdaq-rgls-suntrust-banks-streetwise-report": {
            "title": "Active Runners- Regulus Therapeutics Inc. (NASDAQ:RGLS), SunTrust Banks... - StreetWise Report...",
            "snippet": "StreetWise ReportActive Runners- Regulus Therapeutics Inc. (NASDAQ:RGLS), SunTrust Banks...StreetWise ReportRegales noted that it also made several poster presentations highlighting the pharmacokinetics and pharmacodynamics of RG-101 in healthy...",
            "date": "2015-04-27",
            "categories": "pharmacokinetics,pharmacodynamics",
            "tags": "healthy,presentations,presentations-highlighting,highlighting,noted,regulus,regulus_therapeutics,therapeutics,pharmacokinetics,pharmacodynamics",
            "recuweb_url": "http://en.recuweb.com/pharmacodynamics/streetwisereport.com/2015/04/active-runners-regulus-therapeutics-inc-nasdaq-rgls-suntrust-banks-streetwise-report",
            "resource_url": "http://news.google.com/?hl=en&q=pharmacodynamics%2Bpharmacodynamics&output=atom&nord=1",
            "source_url": "http://streetwisereport.com/active-runners-regulus-therapeutics-inc-nasdaqrgls-suntrust-banks-inc-nysesti-abbvie-inc-nyseabbv/115501/"
        },
        "markets.financialcontent.com/2015/04/critical-outcome-technologies-files-investigational-new-drug-application-with-the-fda": {
            "title": "Critical Outcome Technologies Files Investigational New Drug Application With the FDA for COTI-2...",
            "snippet": "The IND application is a complete description of the chemistry, non-clinical pharmacodynamics and pharmacokinetics, safety toxicology, manufacturing and other relevant information related to COTI-2 as a potential treatment for patients with p53...",
            "date": "2015-04-27",
            "categories": "toxicology,chemistry,pharmacodynamics,pharmacokinetics",
            "tags": "treatment,patients,information,safety,drug,clinical,pharmacodynamics,pharmacokinetics",
            "recuweb_url": "http://en.recuweb.com/pharmacokinetics/markets.financialcontent.com/2015/04/critical-outcome-technologies-files-investigational-new-drug-application-with-the-fda",
            "resource_url": "http://www.bing.com/news/search?first=1&q=pharmacodynamics&format=RSS&cc=us",
            "source_url": "http://markets.financialcontent.com/stocks/news/read?GUID=29746297"
        },
        "satprnews.com/2015/04/late-breaking-oral-presentation-at-the-international-liver-congress-ilc-satellite": {
            "title": "Late-Breaking Oral Presentation at The International Liver Congress (ILC... - Satellite PR News...",
            "snippet": "Late-Breaking Oral Presentation at The International Liver Congress (ILC...Satellite PR News (press release)Regulus also made several poster presentations highlighting the pharmacokinetics and pharmacodynamics of RG-101 in healthy volunteers, the...",
            "date": "2015-04-25",
            "categories": "pharmacokinetics,pharmacodynamics",
            "tags": "healthy,healthy-volunteers,volunteers,presentations,presentations-highlighting,highlighting,oral,regulus,pharmacokinetics,pharmacodynamics",
            "recuweb_url": "http://en.recuweb.com/pharmacodynamics/satprnews.com/2015/04/late-breaking-oral-presentation-at-the-international-liver-congress-ilc-satellite",
            "resource_url": "http://news.google.com/?hl=en&q=pharmacodynamics%2Bpharmacodynamics&output=atom&nord=1",
            "source_url": "http://satprnews.com/2015/04/25/late-breaking-oral-presentation-at-the-international-liver-congress-ilc-2015-highlights-rg-101s-potent-durable-and-pan-genotypic-effects-in-diverse-hcv-population/"
        },
        "rttnews.com/2015/04/regulus-therapeutics-presents-new-data-strengthening-profile-of-rg-101": {
            "title": "Regulus Therapeutics Presents New Data Strengthening Profile Of RG-101...",
            "snippet": "Regulus noted that it also made several poster presentations highlighting the pharmacokinetics and pharmacodynamics of RG-101 in healthy volunteers, the preclinical pharmacokinetics, pharmacodynamics, and toxicity of RG-101, and the efficacy of...",
            "date": "2015-04-25",
            "categories": "pharmacokinetics,pharmacodynamics",
            "tags": "healthy,healthy-volunteers,volunteers,presentations,presentations-highlighting,highlighting,noted,regulus,regulus_therapeutics,therapeutics,pharmacokinetics,pharmacodynamics",
            "recuweb_url": "http://en.recuweb.com/pharmacodynamics/rttnews.com/2015/04/regulus-therapeutics-presents-new-data-strengthening-profile-of-rg-101",
            "resource_url": "http://www.bing.com/news/search?first=1&q=pharmacodynamics%2Bpharmacodynamics&format=RSS&cc=us",
            "source_url": "http://rttnews.com/2487502/regulus-therapeutics-presents-new-data-strengthening-profile-of-rg-101.aspx"
        },
        "fnno.com/2015/04/nektar-therapeutics-shares-sinking-lower-down-1-7%": {
            "title": "Nektar Therapeutics Shares Sinking Lower, Down 1.7%...",
            "snippet": "Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. In the past 52 weeks, Nektar...",
            "date": "2015-04-24",
            "categories": "metabolism,drugs,pharmacokinetics,pharmacodynamics,life",
            "tags": "metabolism,distribution,drugs,drug,benefits,therapeutics,pharmacokinetics,pharmacodynamics",
            "recuweb_url": "http://en.recuweb.com/life/fnno.com/2015/04/nektar-therapeutics-shares-sinking-lower-down-1-7%",
            "resource_url": "http://www.bing.com/news/search?first=1&q=pharmacodynamics%2Bpharmacodynamics&format=RSS&cc=us",
            "source_url": "http://fnno.com/story/market-movers/331-nektar-therapeutics-shares-sinking-lower-down-17-auto-generated"
        },
        "medpagetoday.com/2015/04/tabalumab-offers-no-clinical-benefits-to-ra-patients": {
            "title": "Tabalumab Offers No Clinical Benefits to RA Patients...",
            "snippet": "Despite clear pharmacodynamics changes as evidenced by changes in CD20 B cells, RF rheumatoid factor, and immunoglobulins following tabalumab treatment, BAFF inhibition with tabalumab was not clinically, functionally, or structurally efficacious...",
            "date": "2015-04-24",
            "categories": "pharmacodynamics",
            "tags": "treatment,clinical,benefits,patients,pharmacodynamics",
            "recuweb_url": "http://en.recuweb.com/pharmacodynamics/medpagetoday.com/2015/04/tabalumab-offers-no-clinical-benefits-to-ra-patients",
            "resource_url": "http://www.bing.com/news/search?first=1&q=pharmacodynamics&format=RSS&cc=us",
            "source_url": "http://medpagetoday.com/Rheumatology/Arthritis/51186"
        },
        "nephrologynews.com/2015/04/genzyme-begins-phase-2-clinical-trial-to-evaluate-oral-therapy": {
            "title": "Genzyme begins phase 2 clinical trial to evaluate oral therapy for Fabry disease...",
            "snippet": "Genzyme announced that patients have begun treatment in a Phase 2a clinical trial focused on evaluating the pharmacodynamics of GZ/SAR402671, a new oral substrate reduction therapy being investigated for the treatment of Fabry disease. The safety...",
            "date": "2015-04-23",
            "categories": "therapy,pharmacodynamics",
            "tags": "oral,oral-substrate,oral-substrate-reduction,substrate,substrate-reduction,substrate-reduction-therapy,reduction,reduction-therapy,reduction-therapy-being,therapy,therapy-being,therapy-being-investigated,investigated,treatment,clinical,clinical-trial,clinical-trial-focused,trial,trial-focused,focused,focused-on-evaluating,evaluating,announced,announced-that-patients,patients,patients-have-begun,begun,begun-treatment,evaluate,begins,phase,genzyme,fabry,disease,pharmacodynamics,sar,safety",
            "recuweb_url": "http://en.recuweb.com/pharmacodynamics/nephrologynews.com/2015/04/genzyme-begins-phase-2-clinical-trial-to-evaluate-oral-therapy",
            "resource_url": "http://www.bing.com/news/search?first=1&q=pharmacodynamics&format=RSS&cc=us",
            "source_url": "http://nephrologynews.com/articles/110852-genzyme-begins-phase-2-clinical-trial-to-evaluate-oral-therapy-for-fabry-disease"
        },
        "finanznachrichten.de/2015/04/sensorion-successfully-completes-the-first-part-of-clinical-trial-on-sens": {
            "title": "Sensorion Successfully Completes the First Part of the Clinical Trial on SENS-111, Which Aims to...",
            "snippet": "a pharmacodynamics test used in clinical practice by ENT specialists on patients suffering from dizziness. This study, for which the recruitment of healthy volunteers began in January 2015, comprises two parts: Part 1: a study of single oral doses...",
            "date": "2015-04-23",
            "categories": "recruitment,pharmacodynamics",
            "tags": "oral,part,healthy,healthy-volunteers,volunteers,patients,clinical,clinical_trial,trial,pharmacodynamics",
            "recuweb_url": "http://en.recuweb.com/pharmacodynamics/finanznachrichten.de/2015/04/sensorion-successfully-completes-the-first-part-of-clinical-trial-on-sens",
            "resource_url": "http://www.bing.com/news/search?first=1&q=pharmacodynamics&format=RSS&cc=us",
            "source_url": "http://finanznachrichten.de/nachrichten-2015-04/33498318-sensorion-successfully-completes-the-first-part-of-the-clinical-trial-on-sens-111-which-aims-to-treat-severe-bouts-of-vertigo-004.htm"
        },
        "streetinsider.com/2015/04/genzyme-sny-begins-gz-sar402671-phase-2a-treatment": {
            "title": "Genzyme (SNY) Begins GZ/SAR402671 Phase 2a Treatment...",
            "snippet": "Genzyme, a Sanofi (NYSE: SNY) company, announced that patients have begun treatment in a Phase 2a clinical trial focused on evaluating the pharmacodynamics of GZ/SAR402671, a new oral substrate reduction therapy being investigated for the treatment...",
            "date": "2015-04-21",
            "categories": "therapy,pharmacodynamics",
            "tags": "oral,oral-substrate,oral-substrate-reduction,substrate,substrate-reduction,substrate-reduction-therapy,reduction,reduction-therapy,reduction-therapy-being,therapy,therapy-being,therapy-being-investigated,investigated,treatment,clinical,clinical-trial,clinical-trial-focused,trial,trial-focused,focused,focused-on-evaluating,evaluating,announced,announced-that-patients,patients,patients-have-begun,begun,begun-treatment,genzyme,begins,sar,phase,sanofi,company,pharmacodynamics",
            "recuweb_url": "http://en.recuweb.com/pharmacodynamics/streetinsider.com/2015/04/genzyme-sny-begins-gz-sar402671-phase-2a-treatment",
            "resource_url": "http://www.bing.com/news/search?first=1&q=pharmacodynamics&format=RSS&cc=us",
            "source_url": "http://streetinsider.com/Corporate+News/Genzyme+(SNY)+Begins+GZSAR402671+Phase+2a+Treatment/10475169.html"
        },
        "businesswire.com/2015/04/genzyme-initiates-phase-2a-clinical-trial-to-evaluate-oral-therapy": {
            "title": "Genzyme Initiates Phase 2a Clinical Trial to Evaluate Oral Therapy for Fabry Disease...",
            "snippet": "CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company, announced today that patients have begun treatment in a Phase 2a clinical trial focused on evaluating the pharmacodynamics of GZ/SAR402671, a new oral substrate reduction therapy being...",
            "date": "2015-04-21",
            "categories": "therapy,business,pharmacodynamics",
            "tags": "oral,oral-substrate,oral-substrate-reduction,substrate,substrate-reduction,substrate-reduction-therapy,reduction,reduction-therapy,reduction-therapy-being,therapy,therapy-being,clinical,clinical_trial,clinical-trial-focused,trial,trial-focused,focused,focused-on-evaluating,evaluating,announced,patients,patients-have-begun,begun,begun-treatment,treatment,fabry,disease,evaluate,genzyme,phase,sanofi,company,pharmacodynamics,sar",
            "recuweb_url": "http://en.recuweb.com/pharmacodynamics/businesswire.com/2015/04/genzyme-initiates-phase-2a-clinical-trial-to-evaluate-oral-therapy",
            "resource_url": "http://www.bing.com/news/search?first=1&q=pharmacodynamics&format=RSS&cc=us",
            "source_url": "http://businesswire.com/news/home/20150421005272/en/Genzyme-Initiates-Phase-2a-Clinical-Trial-Evaluate"
        }
    }
}